Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
News|Articles|November 17, 2026

Commit Biologics Raises $60 Million to Take Complement-Powered Immune Engager COM002 Into the Clinic

Listen
0:00 / 0:00

Key Takeaways

  • A $60 million seed financing led by Ackermans & van Haaren will fund COM002 IND-enabling work, an IND submission, progression of a second program, and broader BiCE pipeline buildout.
  • COM002 is a dual-targeting BiCE designed for targeted immune cell depletion, prioritized for relapsed/refractory non-Hodgkin lymphoma with an early-2028 first-patient dosing goal.
SHOW MORE

Danish biotech Commit Biologics closed a $60 million seed round led by Ackermans & van Haaren, with AbbVie Ventures and M Ventures joining, to advance COM002, a bispecific antibody that recruits complement rather than T cells to eliminate diseased cells.

Commit Biologics announced on November 17, 2026, the final close of a $60 million (€54 million) seed financing to move its first complement-powered immune engager, COM002, toward the clinic.¹ Ackermans & van Haaren led the round, with new investors AbbVie Ventures and M Ventures joining existing investors Bioqube Ventures, Korys, and Novo Holdings.¹

“Commit was founded on a simple idea: that complement, one of the most powerful parts of our immune system, could be deliberately directed against diseased cells.” Thomas L. F. Montgomery Andresen, chief executive officer, Commit Biologics

The Copenhagen- and Aarhus, Denmark-based company, a spin-out from Aarhus University, said the proceeds will fund completion of investigational new drug (IND)-enabling activities and an IND filing for COM002, advance a second program into IND-enabling development, and expand its Bispecific Complement Engager (BiCE) pipeline.¹ Michael Rosenzweig of AbbVie Ventures, Charlotte Kremers of M Ventures, and Lenny Van Steenhuyse of Ackermans & van Haaren will join the company’s board.¹

“Seeing our first development candidate backed by such a strong group of financial and strategic investors is a proud moment for the whole team,” said Thomas L. F. Montgomery Andresen, chief executive officer of Commit Biologics.¹

What is COM002?

COM002 is a dual-targeting BiCE molecule designed for targeted immune cell depletion.¹ Commit nominated it as its first development candidate on November 12, 2026, with relapsed or refractory non-Hodgkin lymphoma as the initial indication and plans to expand into several autoimmune diseases.² The company said it expects to dose the first patient in early 2028.²

The candidate builds on nonhuman primate data Commit reported in November 2025, which showed rapid, deep, and sustained targeted B-cell depletion with no treatment-related safety findings and no systemic cytokine release.²

Alongside the nomination, Commit appointed Anne-Marie Levy Rasmussen as chief operating officer and Benjamin Ole Wolthers, MD, as head of clinical development.²

How does a complement engager work?

The complement system is a cascade of plasma proteins that forms part of innate immunity. Beyond clearing pathogens, it tags and removes damaged or apoptotic cells, and its classical pathway is triggered when the protein C1q binds to antibodies clustered on a cell surface.³

Commit’s platform converts immunoglobulin G (IgG) antibodies into complement-powered immune engagers that recruit C1q to selectively and rapidly eliminate targeted diseased cells.¹ The mechanism does not depend on T cells, and the molecules keep the properties of a conventional IgG antibody, according to the company.¹

According to M Ventures’ Kremers, complement is “among the immune system’s most potent effector mechanisms yet remains largely untapped.”¹

Why look beyond T-cell engagers?

The field of B-cell depletion in autoimmune disease has moved past CD20 monoclonal antibodies toward chimeric antigen receptor T-cell (CAR-T) therapy and CD3-based bispecific T-cell engagers, which can produce deeper depletion but also carry risks such as cytokine release syndrome.⁴ Several developers are engineering around that liability. BioPharm International recently reported phase 1 healthy volunteer data for Janux Therapeutics’ JANX011, a CD19-targeted T-cell engager that engages a subset of T cells to limit cytokine release, and covered Sanofi’s license of Kali Therapeutics’ masked tri-specific T-cell engager KT501.

Commit is taking a different route by removing T-cell engagement altogether. Its nonhuman primate results, which showed B-cell depletion without systemic cytokine release, are the basis for that approach, although the platform has not yet been tested in humans.²

Developers and manufacturers point to precision and safety as the direction for next-generation bispecifics. In a BioPharm International® video interview, Atul Mohindra, then head of biologics R&D at Lonza, said, “The need for increasing precision medicine [and] reducing off target events is always going to be there, and I think that’s exactly where the industry needs to head.”

What happens next?

Commit plans to complete IND-enabling work for COM002, file the IND, and enter the clinic, with first patient dosing expected in early 2028.¹˒² The company has not disclosed the two targets of COM002 or the identity of its second program.¹

“Ackermans & van Haaren is proud to lead this financing to realize the full potential of the BiCE platform,” said Lenny Van Steenhuyse, investment manager at Ackermans & van Haaren.¹

References

  1. Commit Biologics announces final close of $60 million seed financing to advance complement-powered immune engagers toward the clinic. News release. Commit Biologics; November 17, 2026. Accessed November 17, 2026.
  2. Commit Biologics nominates first development candidate from BiCE™, its complement system engaging platform, and strengthens senior leadership. News release. Commit Biologics; November 12, 2026. Accessed November 17, 2026.
  3. Ricklin D, Reis ES, Lambris JD. Complement in disease: a defence system turning offensive. Nat Rev Nephrol. 2016;12(7):383-401. doi:10.1038/nrneph.2016.70
  4. Robinson WH, Fiorentino D, Chung L, et al. Cutting-edge approaches to B-cell depletion in autoimmune diseases. Front Immunol. 2024;15:1454747. doi:10.3389/fimmu.2024.1454747

Related to this article